Yesterday, IR Biosciences Holdings’ wholly owned subsidiary, ImmuneRegen BioSciences Inc., announced the execution of an agreement with the National Institute of Health to commence studies utilizing the company’s Homspera. As per the agreement, the NIH will perform exploratory studies on Homspera relating to mucosal immunity that could possibly lead to evaluation in models of HIV infection.

Recent studies have shown Homspera to enhance the efficacy of a novel cancer vaccine. Previous studies have yielded the same results related to infectious disease vaccines, specifically influenza. The studies to be performed at NIH will expand on the previous research and will further define the mechanisms that make Homspera an effective vaccine adjuvant.

The research will be directed by Jay A. Berzofsky, M.D., Ph.D., Chief of the Vaccine Branch at the Center for Cancer Research within the National Cancer Institute. Dr. Berzofsky is the past President of the American Society for Clinical Investigation, and a Fellow of the American Association for the Advancement of Science; additionally, he most recently won the NIH Director’s Award and NCI Merit Award in 2008.

With over 435 scientific publications numerous awards, ImmuneRegen is excited to welcome Berzofsky and his team to the project. Hal Siegel, Ph.D., ImmuneRegen’s Chief Scientific Officer, commented, “We are pleased that Dr. Berzofsky and his team are interested in evaluating the impact of Homspera on mucosal immunity, and hope this is the beginning of a relationship that takes our compound into a number of potential vaccine adjuvant studies.”